Key clinical point: Current guidelines for target systolic BP of 120-129 mm Hg in heart failure with preserved ejection fraction receive validation.
Major finding: PARAGON-HF participants with an systolic BP of 120-129 mm Hg had lowest rates of cardiovascular death and total heart failure hospitalizations.
Study details: PARAGON-HF was an international randomized trial in which 4,822 patients with heart failure with preserved ejection fraction were placed on either sacubitril/valsartan or valsartan alone and prospectively followed for nearly 3 years.
Disclosures: PARAGON-HF was funded by Novartis. The senior author reported receiving research grants from and serving as a consultant to that pharmaceutical company and more than a dozen others.
Solomon SD et al. J Am Coll Cardiol. 2020 Mar 16. doi: 10.1016/j.jacc.2020.02.009.